Tomas Navratil
Net worth: 9 M $ as of 31/05/2026
Net worth: 9 M $ as of 31/05/2026
Dr. Tomas Navratil is a Chief Development Officer at Glaukos Corp.
He is on the Board of Directors at Severomoravske Vodovody a Kanalizace Ostrava as.
Dr. Navratil was previously employed as an Executive VP, Global Head-Research & Development by Nicox SA, a Senior Vice President-Development by Envisia Therapeutics, Inc., a Director-Medical & Scientific Affairs by Inspire Pharmaceuticals, Inc., a General Manager by Nicox Ophthalmics, Inc., and an Executive Director-Clinical Research by Parion Sciences, Inc. He received his undergraduate degree from The University of North Carolina at Charlotte and a doctorate degree from The University of North Carolina at Charlotte.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
GLAUKOS CORP 0.15% | 16/06/2026 | 88,833 ( 0.15% ) | 9 M $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| GLAUKOS CORPORATION | Corporate Officer/Principal | 01/04/2022 |
Severomoravske Vodovody a Kanalizace Ostrava as
Severomoravske Vodovody a Kanalizace Ostrava as Water UtilitiesUtilities Engages in supply of drinking water and sewage services | Director/Board Member | - |
| Companies | Position | End |
|---|---|---|
Nicox Ophthalmics, Inc.
Nicox Ophthalmics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures ophthalmology pharmaceutical products | Corporate Officer/Principal | - |
Inspire Pharmaceuticals, Inc.
Inspire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes ophthalmic products | Chief Tech/Sci/R&D Officer | - |
| NICOX SA | Chief Tech/Sci/R&D Officer | - |
Parion Sciences, Inc.
Parion Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Develops new treatments for serious diseases in multiple therapeutic areas | Corporate Officer/Principal | - |
Envisia Therapeutics, Inc.
Envisia Therapeutics, Inc. BiotechnologyHealth Technology Develops novel ocular therapies | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 8 |
|---|---|
Inspire Pharmaceuticals, Inc.
Inspire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes ophthalmic products | Health Technology |
Parion Sciences, Inc.
Parion Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Develops new treatments for serious diseases in multiple therapeutic areas | Commercial Services |
Glaukos Corp.
Glaukos Corp. Medical SpecialtiesHealth Technology Operates as an ophthalmic medical device company | Health Technology |
Nicox Ophthalmics, Inc.
Nicox Ophthalmics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures ophthalmology pharmaceutical products | Health Technology |
Nicox SA
Nicox SA Pharmaceuticals: MajorHealth Technology Manufactures and sells ophthalmology biopharmaceuticals | Health Technology |
Severomoravske Vodovody a Kanalizace Ostrava as
Severomoravske Vodovody a Kanalizace Ostrava as Water UtilitiesUtilities Engages in supply of drinking water and sewage services | Utilities |
The University of North Carolina at Charlotte
The University of North Carolina at Charlotte Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Envisia Therapeutics, Inc.
Envisia Therapeutics, Inc. BiotechnologyHealth Technology Develops novel ocular therapies | Health Technology |
Select your edition
All financial news and data tailored to specific country editions